Who Exports Isoniazid from India — 127 Suppliers Behind a $2.3B Market
India's isoniazid export market is supplied by 127 active exporters who collectively shipped $2.3B across 3,835 shipments. LUPIN LIMITED leads with a 73.9% market share, followed by MACLEODS PHARMACEUTICALS LTD and MACLEODS PHARMACEUTICALS LIMITED. The top 5 suppliers together control 99.1% of total export value, reflecting a concentrated market structure.
Top Isoniazid Exporters from India — Ranked by Export Value
LUPIN LIMITED is the leading isoniazid exporter from India, holding a 73.9% share of the $2.3B market across 3,835 shipments from 127 exporters. The top 5 suppliers — LUPIN LIMITED, MACLEODS PHARMACEUTICALS LTD, MACLEODS PHARMACEUTICALS LIMITED, MANEESH PHARMACEUTICALS LIMITED, SVIZERA LABS PRIVATE LIMITED — collectively control 99.1% of total export value, indicating a highly concentrated market. Individual shares are: LUPIN LIMITED (73.9%), MACLEODS PHARMACEUTICALS LTD (23.0%), MACLEODS PHARMACEUTICALS LIMITED (1.3%), MANEESH PHARMACEUTICALS LIMITED (0.7%), SVIZERA LABS PRIVATE LIMITED (0.3%).
Top Isoniazid Exporters from India
Ranked by export value · 127 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | LUPIN LIMITED RIFAMPICIN 150MG / ISONIAZID 75MG TABLETS.ISONIAZID 300MG / RIFAPENTINE 300MG COATED TABLETS.ISONIAZID 300 MG/RIFAPENTINE 300 MG COATED TABLETS 3X12S | $1.7B | 78 | 73.9% |
| 2 | MACLEODS PHARMACEUTICALS LTD RIFAMPICIN 150MG / ISONIAZID 75MG TABLETS.ISONIAZID 300MG / RIFAPENTINE 300MG COATED TABLETS.ISONIAZID 300 MG/RIFAPENTINE 300 MG COATED TABLETS 3X12S | $521.0M | 124 | 23.0% |
| 3 | MACLEODS PHARMACEUTICALS LIMITED RIFAMPICIN 150MG / ISONIAZID 75MG TABLETS.ISONIAZID 300MG / RIFAPENTINE 300MG COATED TABLETS.ISONIAZID 300 MG/RIFAPENTINE 300 MG COATED TABLETS 3X12S | $28.5M | 95 | 1.3% |
| 4 | MANEESH PHARMACEUTICALS LIMITED ISONIAZID 300MG / RIFAPENTINE 300MG COATED TABLETS.4 FDC 24X28T GDF RIFAMPICIN, ISONIAZID,RIFAMPIN & ISONIAZID TABLETS 24X28T RIFA | $15.1M | 38 | 0.7% |
| 5 | SVIZERA LABS PRIVATE LIMITED 4 FDC 24X28T GDF RIFAMPICIN, ISONIAZID,RIFAMPIN & ISONIAZID TABLETS 24X28T RIFAISONIAZID 300MG /RIFAPENTINE 300MG COATED TABLETS NOS | $7.2M | 15 | 0.3% |
| 6 | MICRO LABS LIMITED RIFAMPICIN 150MG / ISONIAZID 75MG TABLETS.ISONIAZID 300 MG/RIFAPENTINE 300 MG COATED TABLETS 3X12SISONIAZID 300MG / RIFAPENTINE 300MG COATED TABLETS. | $5.6M | 54 | 0.2% |
| 7 | OMNICALS PHARMA PRIVATE LIMITED ISONIAZID 300MG / RIFAPENTINE 300MG COATED TABLETS.4 FDC 24X28T GDF RIFAMPICIN, ISONIAZID, | $4.2M | 5 | 0.2% |
| 8 | MYLAN LABORATORIES LIMITED RIFAMPICIN 150MG+ISONIAZID 75MG+PYRAZINAMEDICINES. RIFAMPICIN 150MG+ISONIAZID 75 | $3.1M | 14 | 0.1% |
| 9 | MANEESH PHARMACEUTICALS LTD ISONIAZID 300MG / RIFAPENTINE 300MG COATED TABLETS.4 FDC 24X28T GDF RIFAMPICIN, ISONIAZID,RIFAMPIN & ISONIAZID TABLETS 24X28T RIFA | $2.2M | 7 | 0.1% |
| 10 | RECIPHARM PHARMASERVICES PRIVATE LIMITED | $847.2K | 1 | 0.0% |
| 11 | UNILINK PHARMA PRIVATE LIMITED | $787.8K | 2 | 0.0% |
| 12 | CADILA PHARMACEUTICALS LIMITED 4 FDC 24X28T GDF RIFAMPICIN, ISONIAZID,RIFAMPIN & ISONIAZID TABLETS 24X28T RIFAISONIAZID 300MG /RIFAPENTINE 300MG COATED TABLETS NOS | $783.6K | 12 | 0.0% |
| 13 | MEDWISE OVERSEAS PRIVATE LIMITED | $356.8K | 3 | 0.0% |
| 14 | PHAR & VIDE RIFAMPICIN 150MG / ISONIAZID 75MG TABLETS.ISONIAZID 300MG / RIFAPENTINE 300MG COATED TABLETS.ISONIAZID 300 MG/RIFAPENTINE 300 MG COATED TABLETS 3X12S | $236.0K | 2 | 0.0% |
| 15 | AVALOR HEALTH CARE PRIVATE LIMITED | $227.2K | 1 | 0.0% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Isoniazid exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| LUPIN LIMITED | Approved | Yes, 31 March 2025 | No | Not specified | WHO-GMP inspection conducted from 31 March to 4 April 2025. (extranet.who.int) |
| MACLEODS PHARMACEUTICALS LTD | Approved | Yes, 6 February 2023 | No | Not specified | WHO-GMP inspection conducted from 6 to 15 February 2023. (extranet.who.int) |
| MICRO LABS LIMITED | Approved | Yes, 6 December 2022 | No | Not specified | WHO-GMP inspection conducted from 6 to 9 December 2022. (extranet.who.int) |
| MYLAN LABORATORIES LIMITED | Approved | Yes, 10 June 2025 | No | Not specified | WHO-GMP inspection conducted from 10 to 13 June 2025. (extranet.who.int) |
| CADILA PHARMACEUTICALS LIMITED | Approved | Yes, 18 March 2024 | No | Not specified | WHO-GMP inspection conducted from 18 to 22 March 2024. (extranet.who.int) |
| SVIZERA LABS PRIVATE LIMITED | Not Listed | No | No | Not specified | No WHO-GMP or EU GMP certifications found. |
| MANEESH PHARMACEUTICALS LIMITED | Not Listed | No | No | Not specified | No WHO-GMP or EU GMP certifications found. |
| RECIPHARM PHARMASERVICES PRIVATE LIMITED | Not Listed | No | No | Not specified | No WHO-GMP or EU GMP certifications found. |
| OMNICALS PHARMA PRIVATE LIMITED | Not Listed | No | No | Not specified | No WHO-GMP or EU GMP certifications found. |
| UNILINK PHARMA PRIVATE LIMITED | Not Listed | No | No | Not specified | No WHO-GMP or EU GMP certifications found. |
TransData Nexus reviewed the regulatory standing of 10 leading Isoniazid exporters from India. 5 hold US FDA facility approvals, 5 maintain WHO-GMP certification, and 0 are EU GMP compliant. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Isoniazid sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," is renowned for its extensive production of active pharmaceutical ingredients (APIs). The city's pharmaceutical ecosystem is supported by a robust infrastructure, including the Genome Valley and the Hyderabad Pharma City, which provide state-of-the-art facilities for API manufacturing. This concentration of resources and expertise makes Hyderabad a pivotal hub for the production of essential drugs like Isoniazid.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is a significant center for pharmaceutical formulations. Lupin Limited operates a manufacturing facility in Vadodara, specializing in potent and oral contraceptive APIs, as well as oral solid dosage forms. This facility's capabilities align with the production requirements for Isoniazid formulations, contributing substantially to the drug's availability for export.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad region serves as a crucial export gateway for pharmaceutical products. Macleods Pharmaceuticals Ltd, headquartered in Mumbai, leverages this strategic location to facilitate the export of its products, including Isoniazid. The proximity to major ports and international shipping routes enhances the efficiency of distributing pharmaceuticals to global markets. (craft.co)
4Baddi-Nalagarh — Tax Incentive Zone
The Baddi-Nalagarh region in Himachal Pradesh has emerged as a prominent pharmaceutical manufacturing zone, largely due to favorable tax incentives offered by the government. These incentives have attracted numerous pharmaceutical companies to establish manufacturing units in the area, contributing to the overall production capacity of drugs like Isoniazid.
5Sourcing Recommendations
- Diversify Supplier Base: While Lupin Limited and Macleods Pharmaceuticals Ltd dominate Isoniazid exports, consider engaging with other certified manufacturers to mitigate supply chain risks.
- Evaluate Manufacturing Capabilities: Assess the specific manufacturing capabilities of potential suppliers, particularly their experience with anti-tuberculosis medications and compliance with international quality standards.
- Leverage Regional Strengths: Utilize the specialized strengths of different pharmaceutical clusters—such as Hyderabad for APIs and Ahmedabad-Vadodara for formulations—to optimize sourcing strategies.
- Monitor Regulatory Compliance: Ensure that selected suppliers maintain compliance with regulatory standards set by authorities like the US FDA, EMA, and WHO to guarantee product quality and reliability.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Isoniazid exporters from India
LUPIN LIMITED — Lupin acquires five brands from Menarini
Lupin signed an agreement to acquire five legacy brands in gastroenterology, urology, and anti-infectives from Menarini, enhancing its portfolio in India. - IMPACT: This acquisition strengthens Lupin's domestic market presence, potentially increasing resources for Isoniazid production and export.
Impact: This acquisition strengthens Lupin's domestic market presence, potentially increasing resources for Isoniazid production and export.
LUPIN LIMITED — Lupin acquires nine brands from Medical Nutritional Institute
Lupin's South African subsidiary, Pharma Dynamics, acquired nine brands from the Medical Nutritional Institute, expanding its complementary and alternative medicines portfolio. - IMPACT: While focused on the South African market, this acquisition may enhance Lupin's global reach, indirectly supporting Isoniazid export capabilities.
Impact: While focused on the South African market, this acquisition may enhance Lupin's global reach, indirectly supporting Isoniazid export capabilities.
LUPIN LIMITED — Lupin acquires UK-based Renascience Pharma
Lupin Healthcare (UK) Limited acquired Renascience Pharma for £12.3 million, gaining a portfolio of specialty pharmaceutical products in the UK. - IMPACT: This acquisition bolsters Lupin's presence in the UK, potentially facilitating increased Isoniazid exports to European markets.
Impact: This acquisition bolsters Lupin's presence in the UK, potentially facilitating increased Isoniazid exports to European markets.
Common Questions — Isoniazid Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which isoniazid supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, LUPIN LIMITED leads with 769 recorded shipments worth $1.7B. MACLEODS PHARMACEUTICALS LTD (1,391 shipments) and MACLEODS PHARMACEUTICALS LIMITED (479 shipments) are also established high-volume exporters.
Q How many isoniazid manufacturers are there in India?
India has 127 active isoniazid exporters with a combined export market of $2.3B across 3,835 shipments to 163 countries. The top 5 suppliers hold 99.1% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for isoniazid from India?
Average FOB unit price: $6.39 per unit, ranging from $0.00 to $124.50. Average shipment value: $591.5K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 127 verified Indian exporters of Isoniazid ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 3,835 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 163 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
3,835 Verified Shipments
127 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists